Iratumumab is a human monoclonal antibody that targets CD30 antigen. CD30 is overexpressed in various lymphoproliferative disorders, Hodgkin disease, other lymphomas, and other cancers.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.